Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407863 | 0.87 | F10 (0.44) | GPR55ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL5408430 | 0.86 | ALDH1A1 (0.47) | GPR55ALDH1A1KMT2AMEN1HTT | |
| SCHEMBL5409979 | 0.84 | ALDH1A1 (0.45) | GPR55ALDH1A1KMT2AMEN1HTT | |
| SCHEMBL5419673 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL5413005 | 0.82 | MAPT (0.51) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL5415620 | 0.81 | LMNA (0.49) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL5412985 | 0.81 | PDE5A (0.49) | ALDH1A1KMT2AHTTSMN1; SMN2KDM4E | |
| SCHEMBL5413011 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL6794752 | 0.79 | SMN1; SMN2 (0.44) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL5405163 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259168-B2 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2007-08-21 | — | — | US | claimed |
| EP-1294729-B1 | 2-AMINOALKYL-THIENO[2,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2004-09-15 | — | — | EP | claimed |
| US-20040044011-A1 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | MEREK PATENT GMBH (DE) | 2004-03-04 | — | — | US | claimed |
| EP-1294729-A1 | 2-AMINOALKYL-THIENO[2,3-D]PYRIMIDINES | MERCK PATENT GmbH (DE) | 2003-03-26 | — | — | EP | claimed |
| WO-2002000664-A1 | 2-AMINOALKYL-THIENO[2,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2002-01-03 | — | — | WO | claimed |
| US-7259168-B2 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| EP-1294729-B1 | 2-AMINOALKYL-THIENO[2,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2004-09-15 | — | — | EP | disclosed |
| US-20040044011-A1 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | MEREK PATENT GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044011-A1 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | DPYD, PDE3A, PDE2A | GPR55 1291/4885CNR1 1559/4885CNR2 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.